1Kneller A,Rasuda P,Hardan I,et al.Therapy with thalidomide in refractory multiple myeloma patients:the revival of an old drug.Br J Haematol,2000,108:391～393.
2Yaccoby S,Johnson CL,Mahaffey SC,et al.Antimyeloma efficacy of thalidomide in the SCID-hu model.Blood,2002,100(12):4162～4168.
3Mohty M,Stoppa AM,Blaise D,et al.Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide.J Leukoc Biol,2002,72(5):939～945.
4Kakimoto T,Hattori Y,Okamoto S,et al.Thalidomide for the treatment of refractory multiple myeloma:association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.Jpn J Cancer Res,2002,93:1029～1036.
5Rajkumar SV,wizig TE.A review of anglogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.Cancer Treat Rev,2000,20:351～362.
6Singhal S,Mehta J,Desikan R,et a1.Antitumor activity of thalidomide in refractory multiple myeloma.Engl J Med,l999,341(12):l565-1571
3Bohle AS, Kalthoff H. Molecular mechanisms of tumor metastasis and an- giogenesis[J]. Langenbecks Arch Surg, 1999,384(2) : 133-140.
4San-M, iguel JF, Schlag R, Khageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J]. N Engl J Med, 2008,359 (9) :906-917.
